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Background: This multicenter, double-blind, placebo-controlled study assessed the efficacy of rotigotine
transdermal patch on apathy and motor symptoms in patients with Parkinson’s disease (PD).
Methods: Patients with PD-associated apathy (Unified Parkinson's Disease Rating Scale [UPDRS] I item 4
[motivation] ≥2 and patient-rated Apathy Scale [AS] ≥14) were randomized 1:1:1 to “low-dose” rotigotine
(≤6 mg/24 h for early PD [those not receiving levodopa] or ≤8 mg/24 h for advanced PD [those receiving
levodopa]), “high-dose” rotigotine (≤8 mg/24 h for early PD or ≤16 mg/24 h for advanced PD), or placebo, and
maintained at optimal/maximal dose for 12 weeks. Coprimary efficacy variables were: change from baseline to End
of Maintenance in patient-rated AS and UPDRS II + III total score. Recruitment was stopped after an interim futility
analysis; therefore, all p values are exploratory.
Results: Of 122 patients randomized, 81.1 % completed the study (placebo, n = 32/40 [80.0 %]; low-dose rotigotine,
n = 30/41 [73.2 %]; high-dose rotigotine, n = 37/41 [90.2 %]). No treatment difference was observed in the change
in patient-rated AS (least squares mean [95 % confidence interval (CI)] difference: low-dose, 0.04 [−2.42, 2.50],
p =0.977; high-dose, −0.22 [−2.61, 2.18], p = 0.859). Rotigotine improved UPDRS II + III total scores versus placebo
(least squares mean [95 % CI] treatment difference: low-dose, −7.29 [−12.30, −2.28], p = 0.005; high-dose, −6.06 [−10.
90, −1.21], p = 0.015), and the “mood/apathy” domain of the Non-Motor Symptom Scale as rated by the investigator
(secondary outcome). The most frequent adverse events in rotigotine-treated patients were application site
reactions, somnolence, and nausea.
Conclusions: Rotigotine did not improve PD-associated apathy as rated by the patient but provided clinically
relevant improvement in motor control and activities of daily living.
Trial registration: ClinicalTrials.gov identifier NCT01782222. Trial registration date: January 30, 2013.
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Apathy is defined as a lack of motivation characterized
by diminished goal-oriented behavior and cognition [1].
It is very common in patients with Parkinson’s disease
(PD), with prevalence rates ranging from 17 % to 60 %
[2–4]. A recent meta-analysis of apathy in PD reported a* Correspondence: rhauser@health.usf.edu
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[CI]: 34.6 %, 45.0 %) [3]. Several studies have suggested
that apathy is one of the most challenging nonmotor
symptoms faced by patients with PD, affecting both
quality of life and caregiver burden [3, 5, 6]. Although
apathy is observed in both early and advanced stages
of PD [7], apathy in PD is associated with older age,
depression, cognitive impairment, worse motor symp-
toms, and more severe disability [3]. Nonetheless,
almost half of all apathy in PD occurs in patients
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monly used to treat the motor symptoms of PD,
their effects on the neuropsychiatric symptoms of
PD, including apathy, have been less widely studied.
In MPTP-lesioned monkeys, dopaminergic dysfunc-
tion within the ventral tegmental-nucleus accumbens
(VTA-NAcc) pathway has been shown to predict
apathetic behaviors, suggesting that DAs might be
useful to treat apathy symptoms [8]. Rotigotine is a
nonergolinic DA; delivery via a transdermal patch
maintains stable plasma levels over 24 hours with a
single daily application [9]. In a randomized placebo-
controlled study (RECOVER) [10], the Non-Motor
Symptom Scale (NMSS) [11, 12] total score, an
exploratory outcome, improved with rotigotine com-
pared with placebo, as did individual domain scores
for “sleep/fatigue” and “mood/apathy”. A post hoc
analysis showed that within the “mood/apathy”
domain, there were differences in favor of rotigotine
in 4 of 6 validated items: “lost interest in surround-
ings”, “lost interest in doing things”, “seems sad or
depressed”, and “difficulty experiencing pleasure”
[13]. Based on these results, we sought to prospect-
ively evaluate rotigotine for the treatment of apathy
and motor symptoms in patients with PD and asso-
ciated apathy.Methods
Overview
PD0005 was a 29-week, multinational, randomized,
double-blind, placebo-controlled, 3-arm, phase 4
study that assessed the efficacy of rotigotine on PD-
associated apathy and motor symptoms (Clinical-
Trials.gov: NCT01782222). Randomization was strati-
fied by disease stage at baseline: early-stage PD
(defined as those not taking levodopa) or advanced-
stage PD (defined as those taking levodopa). Patients
were randomized 1:1:1 to low-dose rotigotine (up to
6 mg/24 h for early PD and 8 mg/24 h for advanced
PD, as per dosing recommendations in the United
States), high-dose rotigotine (up to 8 mg/24 h for
early PD and 16 mg/24 h for advanced PD, as per
dosing recommendations elsewhere), or placebo. The
study included a screening period of up to 4 weeks,
a titration period of up to 4 weeks for early PD and
up to 7 weeks for advanced PD, a 12-week mainten-
ance period, a de-escalation period of up to 12 days,
and a safety evaluation 28 days after the last dose of
study medication. An interim analysis for futility was
planned after approximately 120 patients had been
randomized and provided data for the coprimary out-
come measure (patient-rated Apathy Scale [AS] score
change from baseline to End of Maintenance [EoM]).Patients were enrolled at 19 sites in the United States
and 11 sites in Europe: Austria (2 sites), Hungary (2
sites), Poland (3 sites), Slovakia (3 sites), and Spain (1
site) from February 2013 to March 2014.
Patients were assigned to treatment using a
computer-generated randomization allocation schedule
prepared by UCB Pharma and implemented through
an interactive voice/web response system. Investiga-
tors, site staff, patients, and monitoring personnel
remained blinded to treatment allocation throughout
the study.
Ethics, consent, and permissions
The study was conducted in accordance with principles
of Good Clinical Practice and the Declaration of
Helsinki, and was approved by appropriate institutional
review boards and ethics committees (Additional file 1).
Written informed consent was obtained from each
patient prior to participation.
Patients
Key inclusion criteria included: ≥18 years old at
screening; diagnosis of PD defined by bradykinesia
plus at least 1 of the following: resting tremor,
rigidity, or postural impairment, and without any
other known or suspected causes of parkinsonism;
unsatisfactory control of PD motor symptoms under
current treatment; Hoehn-Yahr stage 1–4 in the
“ON” state; if taking levodopa, on a stable dose
≥200 mg/day (in combination with benserazide or
carbidopa) for at least 28 days prior to baseline;
apathy associated with PD present for ≥3 months with
Unified Parkinson's Disease Rating Scale (UPDRS) Part I
item 4 score (motivation) ≥2 and mean AS score ≥14 as
rated by the patient; and Mini Mental State Examination
score ≥25.
Key exclusion criteria included: atypical or second-
ary parkinsonism; history of deep brain stimulation;
prior DA therapy within 28 days of baseline; previous
discontinuation of a DA (after sufficient duration at
adequate dose) owing to lack of efficacy as assessed
by the investigator; evidence of an impulse control
disorder according to the modified Minnesota Impul-
sive Disorders Interview (mMIDI); severe depression
(Beck Depression Inventory Second Edition [BDI-II]
score ≥29); lifetime history of suicide attempt or sui-
cidal ideation in past 6 months; current psychother-
apy or behavior therapy; lactating or pregnant; and
substance abuse in the past 6 months.
Monoamine oxidase B inhibitors, anticholinergic
agents, entacapone, amantadine, and central nervous
system therapy (e.g., sedatives, hypnotics, antidepres-
sants, anxiolytics) were permitted if at stable doses
for at least 28 days prior to baseline, and expected to
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medications included DAs, dopamine-modulating or
-releasing substances, neuroleptics (except clozapine
and quetiapine), monoamine oxidase A inhibitors, α-
methyldopa, metoclopramide, budipine, and tolcapone.Study medication
Rotigotine transdermal patches and matching placebo
were supplied by UCB Pharma (Monheim am Rhein,
Germany). Active patches released 2 mg/24 h
(10 cm2), 4 mg/24 h (20 cm2), 6 mg/24 h (30 cm2),
or 8 mg/24 h (40 cm2). During the study patients
applied 1 to 3 patches per day depending on their
assigned daily dose. Rotigotine (or placebo) was
administered once daily, starting at 2 mg/24 h in
patients with early PD and 4 mg/24 h in patients with
advanced PD. Doses were then uptitrated in weekly
increments of 2 mg/24 h per week until the optimal or
maximal dose was reached. The dose of study medication
was considered optimal if both the patient and the investi-
gator felt that PD symptoms, including PD-associated
apathy, were adequately controlled. The patient then
entered the 12-week maintenance period on the
optimal or maximal assigned dose. If during titration
an adverse event (AE) occurred that was thought to
be due to study medication (excessive dopaminergic
stimulation), 1 back-titration to the previous dose
level was allowed and the patient was then entered
into the maintenance phase on that dose. No dose
changes were permitted during the maintenance
period. Following the 12-week maintenance period,
patients de-escalated their study medication dose by
2 mg/24 h every other day.Efficacy assessments
Following baseline evaluations, patients entered the
titration period and were contacted by phone at day
7 and evaluated in person on days 14, 21, 28, 35, and
42, as appropriate for the duration of their dose titra-
tion. They were then evaluated in person on mainten-
ance days 1, 29, and 85 (EoM). A follow-up safety
visit was conducted 28 days following medication
withdrawal. Patients who withdrew prematurely were
asked to return for a withdrawal visit.
Efficacy assessments performed at baseline and
maintenance days 1, 29, and 85 (EoM) included the
AS [14] as rated by the patient, AS as rated by the
caregiver (if available, and with the same caregiver
throughout), UPDRS Parts II + III, Snaith–Hamilton
Pleasure Scale (SHAPS), and the 8-item Parkinson's
Disease Questionnaire (PDQ-8). Efficacy assessments
performed at baseline and maintenance day 85 (EoM)
included the NMSS [11, 12], Fatigue Severity Scale(FSS), BDI-II, Montreal Cognitive Assessment, Clinical
Global Impression (CGI) item 1, and Patient Global
Impression of Change.
The AS [14] is an abbreviated version of the Apathy
Evaluation Scale [15] developed specifically for pa-
tients with PD, and with proven reliability and validity
in assessing apathy in patients with PD. The AS con-
sists of 14 questions that are answered by the patient
or caregiver (where appropriate) on a 4-point scale.
The total AS score is calculated by summing the sin-
gle scores, with higher scores indicating more severe
apathy; a total score of ≥14 is indicative of clinically
relevant apathy symptoms.
Coprimary, secondary, and other efficacy variables
The coprimary efficacy variables were the change from
baseline to EoM in the (1) AS score as rated by the
patient and (2) UPDRS II + III total score. Secondary
efficacy variables were change from baseline to EoM
in the AS score as rated by the caregiver (where avail-
able), PDQ-8, SHAPS, and UPDRS III during “ON”,
and change from baseline to End of Treatment (EoT;
combined data from EoM visit and early withdrawal
visit) in the “mood/apathy” domain of the NMSS,
BDI-II, and CGI item 1 (severity of illness). Other effi-
cacy variables included change from baseline to EoM
in UPDRS II during “OFF”, change from baseline to
EoT in NMSS total score, individual NMSS domains
excluding “mood/apathy”, FSS, and Montreal Cognitive
Assessment. Patient Global Impression of Change at
EoT also was evaluated.
Post hoc analysis of NMSS “mood/apathy” domain
A post hoc analysis was conducted to assess the
change from baseline to EoT in the 6 items that com-
prise the “mood/apathy” domain: item 7 “lost interest
in surroundings”, item 8 “lost interest in doing
things”, item 9 “feels nervous, worried for no reason”,
item 10 “seems sad or depressed”, item 11 “has flat
moods”, and item 12 “difficulty experiencing pleas-
ure”. In addition, the results of the 4 items relating
specifically to apathy (items 7, 8, 11, and 12) were
combined and assessed.
Safety
Safety was assessed by review of AEs, laboratory
values, vital signs, and electrocardiograms. Add-
itional safety assessments included the Columbia-
Suicide Severity Rating Scale, which was conducted
at every in-person visit, and the mMIDI, which was
conducted at maintenance days 1 and 85, and at the
follow-up safety visit. Analysis of safety variables was
performed on the Safety Set, which included all
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study medication.
Statistical analyses
The Full Analysis Set (FAS) was used for analyses of
the coprimary, secondary, and other efficacy vari-
ables, and included all patients who were random-
ized, received at least 1 dose of study medication,
and had valid primary efficacy baseline measure-
ments and at least 1 valid post-baseline maintenance
or valid withdrawal primary efficacy measurement
for both primary efficacy variables. Missing data
were imputed using last observation carried forward,
except for variables that were assessed at only
baseline and EoM. The treatment comparison of pri-
mary interest was each rotigotine dose group versus
placebo. Estimates of treatment effect for the
coprimary efficacy variables were obtained from an
analysis of covariance (ANCOVA) model that in-
cluded treatment and disease stage as factors, and
baseline value as covariate. For each pairwise com-
parison of active treatment with placebo, a 2-sided t
test based on least squares (LS) means with 95 % CI
was performed. Secondary variables and the post hoc
analysis of the single items of the NMSS “mood/ap-
athy” domain were analyzed according to a similar
ANCOVA model as used for the primary variables.
As recruitment into the study was stopped after an
interim futility analysis, all p-values are exploratory.
Other efficacy variables are presented descriptively.
Power calculations
The study was powered for the coprimary efficacy
variables. For the AS, an anticipated clinically mean-
ingful difference between rotigotine and placebo of
3.0 for change from baseline to EoM and a standard
deviation (SD) of 8.0 were assumed based on previous
studies [16, 17]. A sample size of 151 patients per
treatment arm would permit detection of a difference
between rotigotine and placebo with 90 % power and
a 2-sided α = 0.05, resulting in a sample size of 453
patients in the FAS. For UPDRS II + III total score, an
anticipated clinically meaningful difference between
rotigotine and placebo of 3.5 for change from baseline
to EoM and a SD of 9.6 were assumed [10]. A sample
size of 160 patients per treatment group would per-
mit detection of a difference between rotigotine and
placebo with 90 % power and a 2-sided α = 0.05,
resulting in a sample size of 480 patients in the effi-
cacy population (FAS).
Interim analysis
When approximately 120 patients were randomized,
enrollment was to be stopped and an interim analysisfor futility performed by an independent statistician.
The interim analysis investigated only the patient-
rated AS score change from baseline to EoM. Other
efficacy variables, including the other primary efficacy
outcome variable (UPDRS II + III total score), were not
considered. The conditional power under the current
trend (CPtrend) [18] was calculated for each of the treat-
ment arms. The CPtrend refers to the probability of con-
cluding a positive result upon completion of the study,
assuming that the population included in the interim ana-
lysis is representative of the complete study population.
The continuation criteria for each treatment arm were
defined by applying the following conditions to change
in AS score from baseline to EoM:
 Treatment difference favoring rotigotine versus
placebo ≥2.5 points
 CPtrend ≥60 %.
The decision plan for the interim analysis indicated
that if these conditions were met for both the high-
and low-dose rotigotine groups, the study would con-
tinue unchanged; if these conditions were met for the
high-dose but not the low-dose rotigotine group, the study
would continue for the high-dose and placebo arms only;
and if these conditions were not met for the high-dose
rotigotine group, the study would be stopped.
Results
The interim analysis was performed when the study
had randomized 122 patients. The FAS for the in-
terim analysis included 120 patients (40 patients in
each treatment group). Continuation criteria for the
high-dose rotigotine group were not met and, conse-
quently, the study was stopped. Therefore, all analyses
provided should be considered descriptive and all p
values considered exploratory.
Patients
A total of 158 patients were enrolled and 122 were
randomized to low-dose rotigotine (n = 41), high-dose
rotigotine (n = 41), or placebo (n = 40) (Fig. 1). Fifty-
six patients were randomized in Europe and 66 in the
United States. Ninety-nine patients completed the
study.
Baseline demographics and patient characteristics are
presented in Table 1. Mean (SD) age was 69.1 (10.1)
years and mean time from diagnosis was 4.5 (4.0) years.
Twenty-six (21.3 %) patients were early stage (i.e., not
receiving levodopa) and 96 (78.7 %) were advanced stage
(i.e., receiving levodopa). Mild depression (BDI-II ≥14)
was present in 57 (46.7 %) patients. Baseline demograph-
ics and patient characteristics were similar across









































Fig. 1 Patient disposition. Abbreviations: AE: adverse event; FAS: Full Analysis Set; SS: Safety Set
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4.8 years) compared with placebo (3.7 years).
Mean (SD) daily study medication dose during the
maintenance period was 7.2 (1.1) mg/24 h in the low-
dose rotigotine group, 9.9 (3.8) mg/24 h in the high-
dose rotigotine group, and 11.6 (4.5) mg/24 h in the
placebo group.Efficacy
Interim analysis
LS mean (standard error) difference for the high-
dose rotigotine group versus placebo for change
from baseline to EoM in AS score as rated by pa-
tients was 0.08 (1.20) and the CPtrend was 0.77 %,
thereby causing the study to be discontinued. There
were slight differences in the FAS used for the in-
terim analysis (n = 120) and the final efficacy analysis
(n = 116). One patient in the high-dose rotigotine
group was not included in the FAS for the interim
analysis, but was included in the FAS for the final
efficacy analysis because of data cleaning that oc-
curred after the interim analysis was performed. Five
additional patients (4 in the low-dose group and 1 in
the high-dose group) were mistakenly included in
the FAS for the interim analysis (but did not have
valid baseline and post-baseline measurements for
both primary efficacy variables) and are therefore
not included in the FAS for the final efficacy ana-
lysis. It was verified that correct assignment of pa-
tients to the FAS for the interim analysis would not
have modified the decision to stop the study.Final analysis
Coprimary efficacy variables
Results of the ANCOVA for change from baseline to EoM
in patient-rated AS are provided in Fig. 2a. Neither low-
dose nor high-dose rotigotine was associated with a
relevant improvement versus placebo (low-dose LS mean
difference to placebo, 0.04, p = 0.977; high-dose LS mean
difference to placebo, −0.22, p = 0.859). Results of the
ANCOVA for change from baseline to EoM in UPDRS II
+ III total scores are provided in Fig. 2b. Similar benefits
were observed for both low- and high-dose rotigotine
versus placebo (low-dose LS mean difference to
placebo, −7.29, p = 0.005; high-dose LS mean difference to
placebo, −6.06, p = 0.015).
Secondary efficacy variables
No marked differences (exploratory p-values >0.05)
were observed between rotigotine and placebo for AS
as rated by the caregiver, PDQ-8, SHAPS, or BDI-II
(Table 2). UPDRS III “ON” scores improved in both
low-dose (p = 0.014) and high-dose (p = 0.013) rotigo-
tine groups compared with placebo (Table 2). Overall,
CGI severity scores shifted to slightly better categories
in all treatment arms.
The “mood/apathy” domain of the NMSS was im-
proved in the high-dose rotigotine group compared
with placebo (p = 0.034), and there was numerical im-
provement in the low-dose group (Table 2). Post hoc
analyses of the 4 apathy items (items 7, 8, 11, 12) of
the NMSS demonstrated improvement in the com-
bined score for both the low- and high-dose rotigo-
tine groups compared with placebo (Table 2).







Male, n (%) 22 (55.0) 27 (65.9) 27 (65.9)
Age, mean ± SD, years 69.0 ± 11.7 68.1 ± 10.5 70.2 ± 8.0
Disease stage, n (%)
Early (i.e., not taking levodopa) 8 (20.0) 9 (22.0) 9 (22.0)
Advanced (i.e., taking levodopa) 32 (80.0) 32 (78.0) 32 (78.0)
With motor fluctuations 18 (45.0) 17 (41.5) 16 (39.0)
Without motor fluctuations 14 (35.0) 15 (36.6) 16 (39.0)
Time since PD diagnosis, mean ± SD, years 3.7 ± 3.7 4.9 ± 4.0 4.8 ± 4.3
Baseline daily levodopa dose, n (%)
<600 mg/day 19 (47.5) 18 (43.9) 20 (48.8)
≥600 mg/day 13 (32.5) 14 (34.1) 12 (29.3)
Cardinal signs, n (%)
Bradykinesia 40 (100) 41 (100) 41 (100)
Rigidity 35 (87.5) 37 (90.2) 40 (97.6)
Resting tremor 28 (70.0) 26 (63.4) 33 (80.5)
Postural instability 25 (62.5) 31 (75.6) 24 (58.5)
Hoehn and Yahr stage, n (%)
0 (no signs of disease) 0 0 0
1 (unilateral disease) 14 (35.0) 4 (9.8) 5 (12.2)
2 (bilateral disease without impairment of balance) 14 (35.0) 13 (31.7) 14 (34.1)
3 (mild to moderate bilateral disease) 11 (27.5) 20 (48.8) 20 (48.8)
4 (severe disability) 1 (2.5) 4 (9.8) 2 (4.9)
5 (wheelchair bound or bedridden unless aided) 0 0 0
Depression at baseline, n (%)
No/minimal depressiona 21 (52.5) 23 (56.1) 21 (51.2)
At least mild depressionb 19 (47.5) 18 (43.9) 20 (48.8)
UPDRS II + III total score, mean ± SD (0–160)c 40.3 ± 19.1 44.4 ± 14.3 39.6 ± 12.4
AS as rated by the patient, mean ± SD (0–42)c 19.7 ± 3.8 20.1 ± 4.4 20.2 ± 4.8
aBaseline Beck Depression Inventory II 0–13
bBaseline Beck Depression Inventory II ≥14
cHigher scores indicate worse ratings
AS: Apathy Scale; PD: Parkinson’s disease; SD: standard deviation; UPDRS: Unified Parkinson's Disease Rating Scale
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The NMSS total score, NMSS “sleep/fatigue” domain,
and FSS score showed numerical benefits for rotigotine
over placebo (Table 3).
Safety
Most patients completed the study in all treatment groups
(placebo, 80.0 %; low-dose rotigotine, 73.2 %; high-dose
rotigotine, 90.2 %) (Fig. 1). The most common reason for
discontinuation was an AE (placebo, 10.0 %; low-dose
rotigotine, 12.2 %; high-dose rotigotine, 7.3 %) (Fig. 1).
Overall incidences of AEs and specific AEs were simi-
lar in placebo- and rotigotine-treated patients (Table 4).Most AEs were mild or moderate in severity (Table 4).
No deaths were reported. Seven patients experienced
serious AEs; 4 of 40 (10.0 %) placebo-treated patients,
including abdominal pain, sepsis, cerebrovascular acci-
dent, and transient ischemic attack, and 3 of 82 (3.7 %)
rotigotine-treated patients, including small intestinal ob-
struction, ileus, abscess, and cerebral hematoma. Only
abdominal pain in the placebo-treated patient was con-
sidered to be related to the study drug. There were no
clinically relevant mean changes or trends in mean
changes for blood pressure, pulse rate, or weight. There










































LS mean (95% CI) difference to placebo, ANCOVA
low dose: 0.04 (–2.42, 2.50); p = 0.977








































LS mean (95% CI) difference to placebo, ANCOVA
low dose: –7.29 (–12.30, –2.28); p = 0.005




B. UPDRS II + III
Fig. 2 Mean change from baseline to End of Maintenance for
coprimary efficacy variables (Full Analysis Set, last observation carried
forward): (a) Apathy Scale as rated by the patient and (b) Unified
Parkinson's Disease Rating Scale II + III total score. Abbreviations:
ANCOVA: analysis of covariance; CI: confidence interval; LS: least
squares; SD: standard deviation; SE, standard error
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82 (3.7 %) rotigotine-treated patients had a positive
finding on 1 mMIDI module, but associated struc-
tured interviews were negative in the rotigotine-
treated patients and an interview was not conducted
in the placebo-treated patient. Some degree of sui-
cidal ideation, as reported on the Columbia-Suicide
Severity Rating Scale, was identified in 4 of 40
(10.0 %) placebo-treated patients (1 reported at base-
line and 3 during the study) and 5 of 82 (6.1 %)
rotigotine-treated patients (all in low-dose rotigotine
group; 4 at baseline, 1 during the study).Discussion
This was the first placebo-controlled study to pro-
spectively assess the effects of a DA on apathy as a
primary outcome measure in patients with PD. The
study was discontinued after a preplanned interim
analysis because continuation criteria were not met
regarding improvement in the AS (as rated by the pa-
tient) in rotigotine versus placebo groups. In the final
analysis, neither low-dose nor high-dose rotigotine
was associated with an improvement in AS scores
versus placebo. However, improvement was observed
in UPDRS II + III total scores in both rotigotine
groups compared with placebo, consistent with rotigo-
tine’s known benefit on motor symptoms and activ-
ities of daily living in patients with PD [19–21].
The AS [14] was chosen as the coprimary outcome
measure to assess apathy following review of the lit-
erature and was in accordance with a recent recom-
mendation by the Movement Disorder Society task
force [22]. However, the sensitivity to change of the
AS is not known, and PD patients with apathy may
have little or no insight into change in their apathy
status. For the change in AS as completed by the
caregiver, there was a larger numerical difference,
with results similar to the anticipated −3.0-point
treatment difference that was initially expected for
the primary variable, suggesting that caregivers might
identify changes of which patients with apathy are
unaware.
The “mood/apathy” domain of the NMSS consists
of 4 apathy items, 1 mood item, and 1 anxiety item.
Notably, in our study, improvement was observed in
the combined score of the 4 apathy items from the
NMSS, and these items were assessed by the study
investigator. This supports the hypothesis that
changes in apathy may be more apparent to an obser-
ver than to the patient, but it is also possible that
these items could be more sensitive to change even if
completed by the patient, and this is an important
area for future study. The “mood/apathy” domain of
the NMSS was improved in the rotigotine RECOVER
study [10], as discussed above, and was the primary
impetus for this trial. Additionally, in a recent study
of rotigotine in PD patients with nonmotor symp-
toms, although rotigotine did not improve the NMSS
total score compared with placebo, the “mood/apathy”
domain was improved [23]. Thus, in each of 3 separ-
ate studies, one of patients with unsatisfactory early-
morning motor symptom control [10], one of patients
presenting with nonmotor features [23], and one of
patients with apathy and unsatisfactory motor control
(current PD0005 study), the “mood/apathy” domain of
the NMSS was improved with rotigotine compared
with placebo. However, unlike the current study, the
Table 2 Mean change from baseline to End of Maintenance/End of Treatment for secondary efficacy variables (Full An lysis Set)
Assessment
(possible score range)a


















































Post hoc analysis of single items from NMSS “mood/apathy” domain
Item 7: Lost interest in
surroundings (0–12)




Item 8: Lost interest in doing
things (0–12)








Item 12: Difficulty experiencing
pleasure (0–12)




Combined score of the 4 apathy
items: 7, 8, 11, and 12 (0–48)




Item 9: Feels nervous, worried for
no reason (0–12)




Item 10: Seems sad or
depressed (0–12)




aHigher scores indicate worse ratings for all assessments
bData are reported as mean change from baseline to End of Maintenance, with last observation carried forward
cData are reported as mean change from Baseline to End of Treatment (combined data from End of Maintenance visit and Early Withdrawal visit nd reported as observed cases
AS: Apathy Scale; BDI-II: Beck Depression Inventory Second Edition; CI: confidence interval; LS: least squares; NMSS: Non-Motor Symptoms Scale; P Q-8: 8-item Parkinson’s Disease Questionnaire; SHAPS: Snaith–































Table 3 Mean change from baseline to End of Maintenance/End of Treatment for other efficacy variables (Full Analysis Set)









(n = 40) (n = 36) (n = 40) (n = 40) (n = 36) (n = 40)
UPDRS Part II in “OFF” (0–52)b 12.9 ± 6.3 12.8 ± 5.1 12.7 ± 5.8 −1.5 ± 3.5 −3.5 ± 4.5 −2.6 ± 3.4
NMSS total score (0–360)c 50.1 ± 34.1 50.9 ± 31.0 58.2 ± 36.8 −6.7 ± 20.5 −19.5 ± 21.9 −20.7 ± 26.2
NMSS domain scorec
Cardiovascular (0–24) 1.7 ± 2.5 1.3 ± 2.4 1.6 ± 2.0 0.3 ± 2.2 0.2 ± 3.1 −0.6 ± 1.6
Sleep/fatigue (0–48) 8.1 ± 5.9 9.9 ± 6.7 10.9 ± 7.5 0.9 ± 7.3 −3.0 ± 7.3 −3.5 ± 6.5
Perception/hallucination (0–36) 0.6 ± 2.0 0.2 ± 1.0 0.4 ± 1.5 0.1 ± 1.6 0.3 ± 1.2 0.1 ± 2.0
Attention/memory (0–36) 5.7 ± 5.2 5.1 ± 4.7 5.6 ± 5.8 −1.2 ± 3.6 −2.2 ± 4.5 0.6 ± 5.9
Gastrointestinal tract (0–36) 3.8 ± 4.1 2.8 ± 3.5 3.9 ± 4.0 0.4 ± 4.0 −0.7 ± 3.8 −1.4 ± 3.6
Urinary (0–36) 6.3 ± 7.6 5.5 ± 6.1 6.7 ± 7.7 −0.6 ± 5.8 −0.3 ± 6.9 −0.7 ± 4.8
Sexual function (0–24) 5.5 ± 7.7 5.9 ± 7.5 6.5 ± 8.7 −1.4 ± 5.8 −2.8 ± 5.4 −2.3 ± 7.6
Miscellaneous (0–48) 5.1 ± 6.5 4.4 ± 6.6 7.0 ± 7.9 −0.7 ± 4.3 −1.2 ± 4.0 −3.2 ± 6.2
FSS (9–63)c 41.9 ± 13.09 40.4 ± 11.08 43.6 ± 12.38 −2.8 ± 11.74 −6.6 ± 13.10 −5.7 ± 8.87
MoCA (0–30)c 26.4 ± 3.43 25.1 ± 3.29 24.8 ± 4.23 0.2 ± 2.24 0.4 ± 2.58 0.3 ± 3.90
Score at EoT, n (%)
PGICc
Improved — — — 11 (27.5) 14 (38.9) 16 (40.0)
No change — — — 28 (70.0) 16 (44.4) 20 (50.0)
Worsened — — — 0 0 2 (5.0)
Missing — — — 1 (2.5) 6 (16.7) 2 (5.0)
aHigher scores indicate worse ratings for all assessments other than MoCA
bData are reported as mean change from Baseline to End of Maintenance, with last observation carried forward
cData are reported as mean change from Baseline to End of Treatment (combined data from End of Maintenance visit and Early Withdrawal visit), and reported as
observed cases
FSS, Fatigue Severity Scale; MoCA: Montreal Cognitive Assessment; NMSS: Non-Motor Symptoms Scale; PGIC: Patient Global Impression of Change; SD: standard
deviation; UPDRS: Unified Parkinson’s Disease Rating Scale
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evaluated separately from the full “apathy/mood” do-
main in the other studies. We also note that the
“mood/apathy” domain of the NMSS was an explora-
tory outcome in all of these studies, and benefit has
not been demonstrated prospectively using this meas-
ure as a primary outcome. Our experience suggests
that the combined 4 apathy items of the NMSS de-
serves further evaluation as a potential outcome
measure for clinical trials of apathy.
PD studies using other assessment scales that also
include apathy/motivational items include: a meta-
analysis of studies of the nonergolinic DA pramipex-
ole, which suggests that pramipexole may improve
mood and motivational items of the UPDRS Part I
[24]; and a comparative cross-sectional study, in
which the use of pramipexole was associated with
lower apathy scores than levodopa or ropinirole, when
assessed by the Neuropsychiatric Inventory apathysubscore [25]. Thus, the benefits observed on apathy
and motivational items may relate to the specific
pharmacological profiles of DA agonists.
In our study, rotigotine was well tolerated, and the
safety profile was consistent with the known safety pro-
file of rotigotine. In addition, the overall completion rate
was acceptable, indicating that clinical trials evaluating
interventions in PD patients with apathy are feasible.
However, further investigation is required to delineate
the best and most appropriate outcome measures. Apathy
remains a burdensome nonmotor feature of PD for which
effective treatments are needed.
Conclusions
In summary, rotigotine did not improve PD-associated
apathy as rated by the patient but provided clinically mean-
ingful improvements in motor control and activities of daily
living versus placebo. Rotigotine was well tolerated, with no
new safety concerns. Further investigation is required to
Table 4 Incidence of TEAEs (Safety Set)a
Placebo Rotigotine low dose Rotigotine high dose Total rotigotine
(n = 40) (n = 41) (n = 41) (N = 82)
Any TEAE, n (%) 27 (67.5) 28 (68.3) 27 (65.9) 55 (67.1)
Mild 12 (30.0) 16 (39.0) 14 (34.1) 30 (36.6)
Moderate 13 (32.5) 9 (22.0) 12 (29.3) 21 (25.6)
Severe 2 (5.0) 3 (7.3) 1 (2.4) 4 (4.9)
Serious TEAE, n (%) 4 (10.0) 2 (4.9) 1 (2.4) 3 (3.7)
Discontinued due to TEAE, n (%) 4 (10.0) 5 (12.2) 3 (7.3) 8 (9.8)
Drug-related TEAEs, n (%) 18 (45.0) 19 (46.3) 18 (43.9) 37 (45.1)
Deaths, n (%) 0 0 0 0
Most common TEAEs ≥5 % in any treatment groupb
Application site reactionsc 3 (7.5) 5 (12.2) 3 (7.3) 8 (9.8)
Nausea 4 (10.0) 4 (9.8) 2 (4.9) 6 (7.3)
Somnolence 3 (7.5) 2 (4.9) 4 (9.8) 6 (7.3)
Depression 2 (5.0) 4 (9.8) 1 (2.4) 5 (6.1)
Fall 2 (5.0) 3 (7.3) 2 (4.9) 5 (6.1)
Constipation 1 (2.5) 2 (4.9) 3 (7.3) 5 (6.1)
Peripheral edema 1 (2.5) 2 (4.9) 3 (7.3) 5 (6.1)
Headache 4 (10.0) 1 (2.4) 3 (7.3) 4 (4.9)
Dyskinesia 2 (5.0) 3 (7.3) 1 (2.4) 4 (4.9)
Fatigue 2 (5.0) 2 (4.9) 1 (2.4) 3 (3.7)
Dry mouth 0 0 3 (7.3) 3 (7.3)
Insomnia 6 (15.0) 1 (2.4) 2 (4.9) 3 (3.7)
Suicidal ideation 3 (7.5) 1 (2.4) 0 1 (1.2)
Rash 2 (5.0) 1 (2.4) 0 1 (1.2)
Tremor 2 (5.0) 1 (2.4) 0 1 (1.2)
Dystonia 2 (5.0) 0 0 0
Vertigo 2 (5.0) 0 0 0
Visual hallucinations 2 (5.0) 0 0 0
aData are number of patients reporting at least 1 adverse event (%)
bMedDRA (Version 16) Preferred Term except for application site reactions
cRefers to High Level Term “application and instillation site reactions”
TEAE: treatment-emergent adverse event
Hauser et al. BMC Neurology  (2016) 16:90 Page 10 of 12determine the most appropriate outcome measures for
clinical trials of apathy in patients with PD.
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